PharVision Advisers’s VTEX VTEX Stock Holding History

PharVision Advisers’s Portfolio VTEX Stock Details VTEX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,928	Closed	-$131K	–	643
2025 Q4	$131K	Sell	34,928 -52,050	-60%	-$214K	0.07%	633
2025 Q3	$381K	Buy	+86,978	New	+$440K	0.21%	98

Other funds holding VTEX

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PharVision Advisers's VTEX Position: Q1 2026 in Review

PharVision Advisers sold out of VTEX (VTEX) in Q1 2026, closing a stake of 34,928 shares — an estimated $131K sold.

PharVision Advisers first reported a position in VTEX in Q3 2025 and held it in 2 quarters. The position peaked at $381K in Q3 2025. 110 funds tracked by Wall St. Rank hold VTEX as of Q1 2026.

PharVision Advisers reported no remaining VTEX position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 34,928 VTEX shares in Q1 2026, an estimated $131K.
PharVision Advisers first reported a position in VTEX in Q3 2025 and held it in 2 quarters.
PharVision Advisers's VTEX position peaked at $381K in Q3 2025.
110 funds tracked by Wall St. Rank held VTEX as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.